Notice of Change in Application Due Date and Award Information for RFA-HL-15-030 "Stem Cell-Derived Blood Products for Therapeutic Use: Technology Improvement (R43/R44)"

Notice Number: NOT-HL-16-464

Key Dates
Release Date: November 16, 2016

Related Announcements
RFA-HL-15-030

Issued by
National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to inform potential applicants of changes to RFA-HL-15-030 "Stem Cell-Derived Blood Products for Therapeutic Use: Technology Improvement (R43/R44)". The following sections of the Funding Opportunity Announcement have been updated to reflect a change in the final Application Due Date (from February 20, 2017 to July 20, 2017) as well as changes to the Award Information.

Part 1. Key Dates

Currently reads:  

Posted Date

November 6, 2014

Open Date (Earliest Submission Date)

January 20, 2015

Letter of Intent Due Date(s)

30 days prior to the application due date

Application Due Date(s)

February 20, 2015 (Phase I or Fast-Track); February 20, 2016 (Phase I; Phase II; or Fast-Track); February 20, 2017 (Phase II only), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s)

Not Applicable

Scientific Merit Review

June 2015, June 2016, June 2017

Advisory Council Review

August 2015, August 2016, August 2017

Earliest Start Date

September 2015, September 2016, September 2017

Expiration Date

February 21, 2017

Due Dates for E.O. 12372

Not Applicable

Modified to read:  

Posted Date

November 6, 2014

Open Date (Earliest Submission Date)

January 20, 2015

Letter of Intent Due Date(s)

30 days prior to the application due date

Application Due Date(s)

February 20, 2015 (Phase I or Fast-Track); February 20, 2016 (Phase I; Phase II; or Fast-Track); July 20, 2017 (Phase II only), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s)

Not Applicable

Scientific Merit Review

June 2015, June 2016, October 2017

Advisory Council Review

August 2015, August 2016, January 2018

Earliest Start Date

September 2015, September 2016, April 2018

Expiration Date

July 21, 2017

Due Dates for E.O. 12372

Not Applicable

Part 2. Section II. Award Information

Funds Available and Anticipated Number of Awards

Currently reads:

NHLBI intends to commit $675,000 in FY 2015, $2,175,000 in FY 2016, $3,000,000 in FY 2017, and $1,500,000 in FY 2018.

NHLBI intends to fund up to 3 new Phase I or Fast-Track SBIR awards in FY 2015, up to 3 new Phase I and 2 new Phase II SBIR awards in FY 2016, and up to 2 new Phase II SBIR awards in FY 2017.

Modified to read:  

NHLBI intends to commit $675,000 in FY 2015, $2,175,000 in FY 2016, $0 in FY 2017, $1,500,000 in FY 2018, and $1,500,000 in FY 2019.

NHLBI intends to fund up to 3 new Phase I or Fast-Track SBIR awards in FY 2015, up to 3 new Phase I and 2 new Phase II SBIR awards in FY 2016, and up to 2 new Phase II SBIR awards in FY 2018.

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Shimian Zou, PhD
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0074
Email: shimian.zou@nih.gov